- Home
- INZY vs IMMP Comparison
INZY vs IMMP Comparison
Compare INZY & IMMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INZY
- IMMP
- Stock Information
- Founded
- INZY 2015
- IMMP 1987
- Country
- INZY United States
- IMMP Australia
- Employees
- INZY N/A
- IMMP N/A
- Industry
- INZY Biotechnology: Pharmaceutical Preparations
- IMMP Biotechnology: Pharmaceutical Preparations
- Sector
- INZY Health Care
- IMMP Health Care
- Exchange
- INZY Nasdaq
- IMMP Nasdaq
- Market Cap
- INZY 255.3M
- IMMP 251.8M
- IPO Year
- INZY 2020
- IMMP N/A
- Fundamental
- Price
- INZY $3.99
- IMMP $1.60
- Analyst Decision
- INZY Buy
- IMMP Buy
- Analyst Count
- INZY 9
- IMMP 1
- Target Price
- INZY $15.22
- IMMP $7.00
- AVG Volume (30 Days)
- INZY 1.3M
- IMMP 97.6K
- Earning Date
- INZY 08-05-2025
- IMMP 02-27-2025
- Dividend Yield
- INZY N/A
- IMMP N/A
- EPS Growth
- INZY N/A
- IMMP N/A
- EPS
- INZY N/A
- IMMP N/A
- Revenue
- INZY N/A
- IMMP $3,019,249.00
- Revenue This Year
- INZY N/A
- IMMP $50.37
- Revenue Next Year
- INZY N/A
- IMMP N/A
- P/E Ratio
- INZY N/A
- IMMP N/A
- Revenue Growth
- INZY N/A
- IMMP 24.11
- 52 Week Low
- INZY $0.72
- IMMP $1.32
- 52 Week High
- INZY $6.24
- IMMP $2.80
- Technical
- Relative Strength Index (RSI)
- INZY 83.59
- IMMP 34.41
- Support Level
- INZY $3.94
- IMMP $1.81
- Resistance Level
- INZY $3.97
- IMMP $1.92
- Average True Range (ATR)
- INZY 0.01
- IMMP 0.08
- MACD
- INZY -0.10
- IMMP -0.03
- Stochastic Oscillator
- INZY 100.00
- IMMP 0.00
About INZY Inozyme Pharma Inc.
Inozyme Pharma Inc is a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of diseases impacting bone health and blood vessel function. The company is focused on developing a novel therapy to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies. Its product candidate, INZ-701, is a soluble, recombinant, genetically engineered fusion protein that is designed to correct a defect in a pathway involving ENPP1 and ABCC6 deficiencies.
About IMMP Immutep Limited
Immutep Ltd is a globally active biotechnology company developing immunotherapy products for cancer and autoimmune diseases. Its main product is IMP321, which involves clinical development for the treatment of cancer indications. The company is also focused on the development of other products, which include IMP701, which is a blocking anti-LAG-3 antibody for cancer and is in Phase I of its clinical trials, and CVac, which is a personalized immunocellular therapeutic investigated for the treatment of epithelial cancer. Geographically all the business activity of the firm is functioned through the region of Australia.